Cancer-related costs should be allocated in a comparable way—benchmarking costs of cancer in Nordic countries 2012–2017

References

• Hofmarcher T, Lindgren P, Wilking N, et al. The cost of cancer in Europe 2018. Eur J Cancer. 2020;129:41–49.
   PubMed Web of Science ®Google Scholar
• Bugge C, Brustugun OT, Saether EM, et al. Phase- and gender-specific, lifetime, and future costs of cancer: a retrospective population-based registry study. Medicine. 2021a;100(26):e26523.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–2917.
   PubMed Web of Science ®Google Scholar
• Møller H, Fairley L, Coupland V, et al. The future burden of cancer in England: Incidence and numbers of new patients in 2020. Br J Cancer. 2007;96(9):1484–1488.
   PubMed Web of Science ®Google Scholar
• Jönsson B, Hofmarcher T, Lindgren P, et al. The cost and burden of cancer in the European Union 1995–2014. Eur J Cancer. 2016;66:162e70–162170.
   Web of Science ®Google Scholar
• Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12(10):933–980.
   PubMed Web of Science ®Google Scholar
• Luengo-Fernandez R, Leal J, Gray A, et al. Economic burden of cancer across the European Union: a population-based cost analysis. Lancet Oncol. 2013;14(12):1165–1174.
   PubMed Web of Science ®Google Scholar
• Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the US: 2010-2020. J Natl Cancer Inst. 2011;103(2):117–128.
   PubMed Web of Science ®Google Scholar
• Kalseth J, Halvorsen T, Kalseth B, et al. Cross-country comparisons of health-care costs: the case of cancer treatment in the Nordic countries. Health Policy. 2014;115(2–3):172–179.
   PubMed Web of Science ®Google Scholar
• Bradley CJ, Yabroff KR, Dahman B, et al. Productivity costs of cancer mortality in the United States: 2000–2020. J Natl Cancer Inst. 2008;100(24):1763–1770.
   PubMedGoogle Scholar
• Warren JL, Yabroff KR, Meekins A, et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst. 2008;100(12):888–897.
   PubMedGoogle Scholar
• Torkki P, Leskela RL, Linna M, et al. Cancer costs and outcomes in the Finnish population 2004–2014. Acta Oncol. 2018;57(2):297e303–297e303.
   Web of Science ®Google Scholar
• Tangka FK, Trogdon JG, Richardson LC, et al. Cancer treatment costs in the United States: has the burden shifted over time? Cancer. 2010;116(14):3477–3484.
   PubMed Web of Science ®Google Scholar
• Aviki E, Abu-Rustum N, Moss H, et al. Cancer care affordability: what is our role? Gynecol Oncol. 2021;162:S101–S102.
   Web of Science ®Google Scholar
• Aggarwal A, Sullivan R. Affordability of cancer care in the United Kingdom–is it time to introduce user charges? J Cancer Policy. 2014;2(2):31–39.
   Google Scholar
• Uyl-de Groot CA, Löwenberg B. Sustainability and affordability of cancer drugs: a novel pricing model. Nat Rev Clin Oncol. 2018;15(7):405–406.
   PubMed Web of Science ®Google Scholar
• Allemani C, Weir HK, Carreira H, et al.; CONCORD Working Group. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977–1010.
   PubMed Web of Science ®Google Scholar
• De Angelis R, Sant M, Coleman MP, et al.; EUROCARE-5 Working Group. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncol. 2014;15(1):23–34.
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Swaminathan R, Brenner H, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 2010;11(2):165–173.
   PubMed Web of Science ®Google Scholar
• Coleman MP, Forman D, Bryant H, ICBP Module 1 Working Group, et al. Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995–2007 (the International Cancer Benchmarking PPartnership): An analysis of population-based cancer registry data. Lancet. 2011;377(9760):127–138.
   PubMed Web of Science ®Google Scholar
• Chapko MK, Liu CF, Perkins M, et al. Equivalence of two healthcare costing methods: bottom-up and top-down. Health Econ. 2009;18(10):1188–1201.
   PubMed Web of Science ®Google Scholar
• Larønningen S, Ferlay J, Bray F, et al. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic Countries, version 9.0 (01.03.2021). Association of the Nordic Cancer Registries. Cancer Registry of Norway; 2021 [cited 2021 Oct 11]. Available from: https://nordcan.iarc.fr/.
   Google Scholar
• OECD. Statistics – health expenditure and financing; 2021 [cited 2021 Aug 22]. OECD. Available from: https://stats.oecd.org/.
   Google Scholar
• Eurostat. Purchasing power parities (PPPs), price level indices and real expenditures for ESA 2010 aggregates [prc_ppp_ind]; 2021 [cited 2021 Aug 22]. Available from: https://ec.europa.eu/eurostat/data/database.
   Google Scholar
• Bugge C, Saether EM, Brustugun OT, et al. Societal cost of cancer in Norway—results of taking a broader cost perspective. Health Policy. 2021b;125(8):1100–1107.
   PubMed Web of Science ®Google Scholar
• Hofmarcher T, Bradvik G, Svedman C, et al. Comparator report on cancer in Europe 2019 – disease burden, costs and access to medicines. Lund: IHE; 2019.
   Google Scholar